Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Rivalry and red tape

Nature volume 436, pages 490–491 (2005)Cite this article

Researchers are suffering as a result of the conflicts between funding agencies. T. V. Padma uncovers plans to heal the rift.

Seth's vaccine research was funded by the Department of Biotechnology (DBT), part of the science ministry. He published his work in peer-reviewed journals and received positive feedback from several evaluation committees. In March 2003, the DBT gave him the green light to form a partnership with an Indian company and manufacture the vaccine for phase I human trials.

This is a preview of subscription content, access via your institution

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

Buy

All prices are NET prices.

Author information

Author notes

  1. T. V. Padma is a freelance writer based in New Delhi.

    • T. V. Padma
Authors
  1. T. V. Padma
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Padma, T. Rivalry and red tape. Nature 436, 490–491 (2005). https://doi.org/10.1038/436490a

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/436490a

This article is cited by

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing